Yana D. Nazarenko

Ms. Yana D. Nazarenko

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
GBGalina V. Baydakova
Galina V. Baydakova
PTPolina Tsygankova
Polina Tsygankova
NPNatalia L. Pechatnikova
Natalia L. Pechatnikova
OBOlga A. Bazhanova
Olga A. Bazhanova
YNYana D. Nazarenko
Yana D. Nazarenko
EZEkaterina Yu. Zakharova
Ekaterina Yu. Zakharova
Long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) and mitochondrial trifunctional protein (MTP) deficiencies are rare fatal disorders of fatty acid β-oxidation with no apparent genotype–phenotype correlation. The measurement of acylcarnitines by MS/MS is a current diagnostic workup in these disorders. Nevertheless, false-positive and false-negative results have been reported, highlighting a necessity for more sensitive and specific biomarkers. This study included 54 patients with LCHAD/MTP deficiency that has been confirmed by biochemical and molecular methods. The analysis of acylcarnitines in dried blood spots was performed using ESI-MS/MS. The established “HADHA ratio” = (C16OH + C18OH + C18:1OH)/C0 was significantly elevated in all 54 affected individuals in comparison to the control group. Apart from 54 LCHAD deficiency patients, the “HADHA ratio” was calculated in 19 patients with very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. As VLCAD-deficient patients did not show increased “HADHA ratio”, the results emphasized the high specificity of this new ratio. Therefore, the “HADHA ratio” was shown to be instrumental in improving the overall performance of MS/MS-based analysis of acylcarnitine levels in the diagnostics of LCHAD/MTP deficiencies. The ratio was demonstrated to increase the sensitivity and specificity of this method and reduce the chances of false-negative results.

Verified
Journal Article
Open access
PDF file
EZEKATERINA ZAKHAROVA
EKATERINA ZAKHAROVA
GBGalina V. Baydakova
Galina V. Baydakova
PBPolina Baranova
Polina Baranova
DADarya Y. Aleksandrova
Darya Y. Aleksandrova
Olga ShchaginaOlga Shchagina
Olga Shchagina
SKSergei I. Kutsev
Sergei I. Kutsev
In 2023, the Russian Federation expanded its national newborn screening (NBS) program from 5 to 36 conditions, 29 of which are inherited metabolic diseases (IMDs). This study presents the first nationwide results and outcomes of the expanded NBS program. Between January 2023 and December 2024, dried blood spots from 2,466,615 newborns (98.53% of the birth cohort) were analyzed for IMDs using MS/MS. Screen-positive cases were referred to the national reference center for confirmatory testing, which included biochemical (MS/MS and GC-MS) and genetic analyses (NGS). A total of 41,728 neonates (1.69%) screened positive, of whom 37,733 underwent confirmatory testing. It resulted in 834 confirmed diagnoses of IMDs (1 in 2900 live births). Phenylketonuria was the most prevalent IMD (n = 538; 1 in 4600), followed by MCADD (n = 99; 1 in 25,000). Distinct regional and ethnic variations were observed, including a high prevalence of tyrosinemia type 1 in the Chechen Republic and MCADD in North Ossetia. The integration of NGS was essential for resolving complex cases, such as identifying heterozygous carriers and dual diagnoses. These findings underscore the program’s clinical utility, highlight unique epidemiological patterns, and identify challenges such as false positives and diagnostic complexities, which will guide future refinements.

13 February 2026 in Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
EGElena A. Gusarova
Elena A. Gusarova
ADAnna V. Degtyareva
Anna V. Degtyareva
ALAlla E. Lavrova
Alla E. Lavrova
TSTatiana V. Strokova
Tatiana V. Strokova
NSNatalia A. Semenova
Natalia A. Semenova
EZEkaterina Y. Zakharova
Ekaterina Y. Zakharova